Thanks for subscribing!
Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)
Ymmunobio Appoints New Chief Operating Officer
Ymmunobio Accepted into Innosuisse Core Coaching
Dr. Katrin Rupalla Interviewed by Global Business Reports
Drug Discovery & Development
Fierce Biotech: Appointment of Michel Janicot
2023 CIMT Annual Meeting Poster Presentation
Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy ...
Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis ...
Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK ...
CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection
CEACAM1 inhibits Toll-like receptor 2–triggered antibact. responses of pulmonary epithelial cells
CEACAM1 (CD66a) mediates delay of spontaneous and Fas ligand-induced apoptosis in granulocytes
Biliary glycoprotein, a cell adhesion molecule of the immunoglobulin superfamily on lymphocytes